Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.
Clinical trial NCT03666273 · COMPLETED
Trial details
- NCT number
- NCT03666273
- Sponsor
- Bayer
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-09-12
- Primary completion
- 2023-06-16
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.